Skip to main content
Premium Trial:

Request an Annual Quote

DNA2.0, Operon Biotechnologies Pen Co-Marketing Alliance

NEW YORK (GenomeWeb News) — Synthetic gene company DNA2.0 and oligonucleotide synthesis shop Operon Biotechnologies today said they have formed a co-marketing alliance.
 
Terms of the deal call for Operon to co-market DNA2.0’s gene-synthesis services, while Operon’s oligos will become the “primary source” of the oligos that go into DNA2.0’s synthetic genes, the companies said.
 
The companies are betting that the alliance will increase DNA2.0's speed of synthesis and give Operon access to what the firms call “the fastest growing application area for oligonucleotides today.”
 
Financial terms of the deal were not disclosed.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.